P
Paraskevi Giannakakou
Researcher at Cornell University
Publications - 162
Citations - 13101
Paraskevi Giannakakou is an academic researcher from Cornell University. The author has contributed to research in topics: Prostate cancer & Taxane. The author has an hindex of 55, co-authored 155 publications receiving 11892 citations. Previous affiliations of Paraskevi Giannakakou include Spanish National Research Council & Emory University.
Papers
More filters
Journal ArticleDOI
Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- 225Ac-J591 for chemo-naive metastatic castration-resistant prostate cancer (mCRPC).
Scott T. Tagawa,Joseph R. Osborne,Matthew Dallos,Jones T. Nauseef,Cora N. Sternberg,Peter Gregos,Amie Patel,Angela Tan,Sharon Singh,Mahelia Bissassar,Ana M. Molina,Paraskevi Giannakakou,Himisha Beltran,David M. Nanus,Karla V. Ballman,Neil H. Bander +15 more
TL;DR: The hypothesis is that the addition of a PSMA-targeted alpha emitter increases the composite of RECIST measurable disease, PSA, and CTC count response to immuno-hormonal therapy with 90% power and will increase the response proportion to pembrolizumab plus ARSI resulting in more durable response.
Proceedings ArticleDOI
Automatic microtubule tracking for QD-based in vivo cell imaging and drug efficacy study.
TL;DR: Active contour-based tracking methods to automatically track microtubule tracking are described, which have been validated using simulated images, images of untreated MCF-7 breast cancer cells, and image of cells treated with the microtubules-targeting chemotherapeutic agent, Taxol.
Proceedings ArticleDOI
Abstract LB-196: A folate receptor-targeted nanoparticle minimizes multidrug resistance in human cancer xenograft model
Xu Wang,Jun Li,Yuxiang Wang,Lydia Koenig,Ada Gjyrezi,Paraskevi Giannakakou,Edwin H. Shin,Mourad Tighiouart,Zhuo (Georgia) Chen,Shuming Nie,Dong M. Shin +10 more
TL;DR: The results indicated that the therapeutic efficacy of targeting HFT-T nanoparticle is significantly superior to free paclitaxel and non-targeted nanoparticle in drug-resistant xenograft models.
Journal ArticleDOI
Abstract 646: Liquid biopsy transcriptomics identify pathways associated with poor outcomes and immune phenotypes in men with mCRPC
Jiaren Zhang,Bob Zimmermann,Giuseppe Galletti,Susan Halabi,Ada Gjyrezi,Qian Yang,Santosh Gupta,Akanksha Verma,Andrea Sboner,Monika Anand,Daniel J. George,Simon G. Gregory,Prerna Mahtani,Seung-Doo Hong,Virginia Pascual,Clio P. Mavragani,Emmanuel S. Antonarakis,David M. Nanus,Scott T. Tagawa,Olivier Elemento,Andrew J. Armstrong,Paraskevi Giannakakou +21 more
TL;DR: It is demonstrated that liquid biopsy transcriptomics of both tumor cells and immune cells can identify molecular pathways associated with treatment resistance paving the way for treatment optimization and the development of novel precision therapies in patients with mCRPC.